Neurocrine Biosciences (NBIX) Scheduled to Post Earnings on Monday

Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to issue its quarterly earnings data after the market closes on Monday, April 29th. Analysts expect the company to announce earnings of ($0.91) per share for the quarter.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Tuesday, February 5th. The company reported $0.19 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.05. The business had revenue of $131.49 million during the quarter, compared to the consensus estimate of $132.32 million. Neurocrine Biosciences had a return on equity of 5.06% and a net margin of 4.68%. The business’s quarterly revenue was up 39.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.07 EPS. On average, analysts expect Neurocrine Biosciences to post $0 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Shares of NBIX stock opened at $78.43 on Monday. The company has a debt-to-equity ratio of 0.81, a current ratio of 8.36 and a quick ratio of 8.24. The company has a market cap of $7.16 billion, a PE ratio of 356.50 and a beta of 1.87. Neurocrine Biosciences has a 1-year low of $64.72 and a 1-year high of $126.98.

NBIX has been the subject of several research analyst reports. Bank of America reduced their target price on Neurocrine Biosciences from $124.00 to $117.00 and set a “buy” rating for the company in a research note on Wednesday, February 6th. HC Wainwright reaffirmed a “buy” rating on shares of Neurocrine Biosciences in a research note on Wednesday, January 30th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $121.00 target price on shares of Neurocrine Biosciences in a research note on Tuesday, January 29th. Oppenheimer set a $105.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Tuesday, January 29th. Finally, ValuEngine upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, February 8th. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $103.48.

In other Neurocrine Biosciences news, insider Kyle Gano sold 3,809 shares of the company’s stock in a transaction on Tuesday, February 5th. The stock was sold at an average price of $88.12, for a total value of $335,649.08. Following the completion of the sale, the insider now directly owns 17,595 shares in the company, valued at approximately $1,550,471.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Kevin Charles Gorman sold 7,614 shares of the company’s stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $88.16, for a total value of $671,250.24. Following the completion of the sale, the chief executive officer now owns 408,082 shares of the company’s stock, valued at $35,976,509.12. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: This story was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/04/22/neurocrine-biosciences-nbix-scheduled-to-post-earnings-on-monday.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Read More: Using the New Google Finance Tool

Earnings History for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.